Results 21 to 30 of about 97,405 (387)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Cells, 2022
The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede   +3 more
doaj   +1 more source

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease

Frontiers in Neurology, 2021
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios, Natalia Palacios, Natalia Palacios, Anas Hannoun, Julie Flahive, Doyle Ward, Doyle Ward, Kelsey Goostrey, Anindita Deb, Kara M. Smith   +9 more
doaj   +1 more source

Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa

Brain : a journal of neurology, 2020
See Poewe and Espay (doi:10.1093/brain/awaa226) for a scientific commentary on this article. Cilia et al. describe the natural course of motor symptoms in drug-naïve patients with Parkinson’s disease and the effects of long-term levodopa on motor ...
R. Cilia, E. Cereda, A. Akpalu, F. Sarfo, M. Cham, Ruth Laryea, Vida Obese, Kenneth Oppon, F. Del Sorbo, Salvatore Bonvegna, A. Zecchinelli, G. Pezzoli   +11 more
semanticscholar   +1 more source

Sonolysis of levodopa and paracetamol in aqueous solutions. [PDF]

, 2009
Pharmaceutical products are often present in wastewater treatment effluents, rivers, lakes and, more rarely, in groundwater. The advanced oxidation methods, like ultrasound, find a promising future in the area of wastewater treatment.
Delmas, Henri, Julcour-Lebigue, Carine, Jáuregui Haza, Ulises Javier, Quesada-Peñate, Isariebel, Wilhelm, Anne-Marie   +4 more
core   +1 more source

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]

, 2003
Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, J.F., Benabid, A.-L., Pollak, P.   +11 more
core   +4 more sources

Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism

Science, 2019
The dope on l-dopa metabolism The efficacy of l-dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota.
Vayu Maini Rekdal, Elizabeth N. Bess, J. Bisanz, P. Turnbaugh, E. Balskus   +4 more
semanticscholar   +1 more source

Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]

, 2014
Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed, Ananth, Aron, Aron, Baldessarini, Breakefield, Brooks, Byl, Calabresi, Calabresi, Carta, Casey, Casey, Castrén, Cenci, Cenci, Cerasa, Cerasa, Cerasa, Cerasa, Cerasa, Clarke, Crow, Crow, de la Fuente-Fernandez, de la Fuente-Fernandez, Fahn, Ganos, Gottwald, Heckers, Jankovic, Jellinger, Jenner, Kishore, Kishore, Koch, Koch, Koch, Li, Marsden, McEwen, Morgante, Nambu, Obeso, Pakkenberg, Peralta, Picconi, Quartarone, Rascol, Rylander, Salgado-Pineda, Sawada, Sgambato-Faure, Sigwald, Spencer, Teo, Vernon, Vernon, Zesiewicz   +58 more
core   +2 more sources

Experience in using levodopa-benserazide

Неврология, нейропсихиатрия, психосоматика, 2015
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova   +3 more
doaj   +1 more source

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes

Frontiers in Neurology, 2021
Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li, Ying-mai Yang, Li-bo Li, Meng-yu Zhang, Yang-yu Huang, Jie Wang, Lin Wang, Xin-hua Wan   +7 more
doaj   +1 more source

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

Nature Communications, 2019
Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria in their ability to decarboxylate levodopa to dopamine
Sebastiaan P. van Kessel, Alexandra K. Frye, A. El-Gendy, M. Castejon, A. Keshavarzian, G. van Dijk, Sahar El Aidy   +6 more
semanticscholar   +1 more source